Related Experiment Videos
Injectable aspirin and mepyramine abolish post-ischaemic hyperalgesia in rats
Linda Gelgor1, Sally Phillips, Neil Butkow
1Department of Physiology, University of the Witwatersrand Medical School, Parktown, Johannesburg 2193 South Africa.
Pain
|September 1, 1986
Summary
Histamine release and prostanoid synthesis contribute to post-ischaemic hyperalgesia in rats. Mepyramine and lysine acetylsalicylate effectively reduced this pain response, indicating their therapeutic potential.
Area of Science:
- Pharmacology
- Pain Research
- Neuroscience
Background:
- Post-ischaemic pain, or hyperalgesia, is a significant clinical challenge.
- Understanding the underlying mechanisms of post-ischaemic hyperalgesia is crucial for developing effective pain management strategies.
Purpose of the Study:
- To investigate the roles of histamine and prostanoids in post-ischaemic hyperalgesia.
- To evaluate the efficacy of an H1 receptor antagonist (mepyramine) and a cyclo-oxygenase inhibitor (lysine acetylsalicylate) in mitigating this pain.
Main Methods:
- Tail ischaemia was induced in conscious rats using a tourniquet method.
- Hyperalgesia was assessed by measuring tail flick latency in hot water (49°C).
- Rats were pretreated with mepyramine maleate or lysine acetylsalicylate before ischaemia induction.
Main Results:
- Ischaemia significantly decreased tail flick latency, indicating hyperalgesia.
- Pretreatment with mepyramine (3 mg/kg) or lysine acetylsalicylate (400 mg/kg) abolished the post-ischaemic decrease in tail flick latency.
- Both drugs were administered subcutaneously and demonstrated significant pain reduction.
Conclusions:
- Histamine release and prostanoid synthesis are key mediators of post-ischaemic hyperalgesia in this rat model.
- Mepyramine and lysine acetylsalicylate show potential for managing post-ischaemic pain by targeting these pathways.